New smallpox vaccine shows promise in early trial
NCT ID NCT00437021
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested an experimental smallpox vaccine called IMVAMUNE in 226 healthy adults who had never received a smallpox vaccine. Participants received either the IMVAMUNE vaccine or a placebo, and researchers monitored their immune responses and any side effects for up to 425 days. The goal was to see if the new vaccine is safe and how well it triggers the body's defenses against smallpox.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMVAMUNE (MVA smallpox vaccine)
What this could lead to
If successful, this could provide a safer smallpox vaccine option for people who have never been vaccinated, especially if the traditional vaccine is too risky.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 226 participants, so results may not apply to everyone. The vaccine may not produce strong enough immunity to protect against smallpox.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALLPOX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Case Western Reserve University - John T. Carey Special Immunology Unit
Cleveland, Ohio, 44106-3808, United States
-
Duke Translational Medicine Institute - Clinical Vaccine Unit
Durham, North Carolina, 27704-2120, United States
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
University of Iowa - Vaccine Research and Education Unit
Iowa City, Iowa, 52242-2600, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
University of Rochester Medical Center - Strong Memorial Hospital - Infectious Diseases
Rochester, New York, 14642-0001, United States
-
University of Texas Medical Branch - Pediatrics - Infectious Diseases and Immunology - Galveston
Galveston, Texas, 77555-5302, United States